Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Maraviroc reduces the regulatory T-cell frequency in antiretroviral-naive HIV-infected subjects.

Pozo-Balado MM, Martínez-Bonet M, Rosado I, Ruiz-Mateos E, Méndez-Lagares G, Rodríguez-Méndez MM, Vidal F, Muñoz-Fernández MA, Pacheco YM, Leal M.

J Infect Dis. 2014 Sep 15;210(6):890-8. doi: 10.1093/infdis/jiu180. Epub 2014 Mar 20.

PMID:
24652492
[PubMed - indexed for MEDLINE]
2.

Severe immune dysregulation affects CD4⁺CD25(hi)FoxP3⁺ regulatory T cells in HIV-infected patients with low-level CD4 T-cell repopulation despite suppressive highly active antiretroviral therapy.

Méndez-Lagares G, Pozo-Balado MM, Genebat M, García Pergañeda A, Leal M, Pacheco YM.

J Infect Dis. 2012 May 15;205(10):1501-9. doi: 10.1093/infdis/jis230. Epub 2012 Mar 28. Erratum in: J Infect Dis. 2012 Dec 15;206(12):1951. del Mar del Pozo Balado, María [corrected to Pozo-Balado, María M]; Genebat González, Miguel [corrected to Genebat, Miguel]; García Pergañeda Sánchez, Antonio [corrected to García-Pergañeda, Antonio]; Leal Noval, Manuel [corrected to Leal, Manuel]; Pacheco López, Yolanda María [corrected to Pacheco, Yolanda María].

PMID:
22457273
[PubMed - indexed for MEDLINE]
Free Article
3.

Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.

Yost R, Pasquale TR, Sahloff EG.

Am J Health Syst Pharm. 2009 Apr 15;66(8):715-26. doi: 10.2146/ajhp080206. Review.

PMID:
19336831
[PubMed - indexed for MEDLINE]
4.

T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.

Pulido I, Machmach K, Romero-Sánchez MC, Genebat M, Mendez-Lagares G, Ruiz-Mateos E, Leal M.

J Infect. 2012 Apr;64(4):417-23. doi: 10.1016/j.jinf.2011.12.017. Epub 2011 Dec 29.

PMID:
22227467
[PubMed - indexed for MEDLINE]
5.

[Maraviroc efficacy in clinical studies on the development of the molecule].

Moreno S, Hernández B, Gutiérrez C, Delsol E.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:17-22. Review. Spanish.

PMID:
19133217
[PubMed - indexed for MEDLINE]
6.

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.

Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, Rajicic N, Valdez H, Lederman MM.

PLoS One. 2010 Oct 6;5(10):e13188. doi: 10.1371/journal.pone.0013188.

PMID:
20949133
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Effect of maraviroc on HIV disease progression-related biomarkers.

Romero-Sánchez MC, Machmach K, Gonzalez-Serna A, Genebat M, Pulido I, García-García M, Alvarez-Ríos AI, Ferrando-Martinez S, Ruiz-Mateos E, Leal M.

Antimicrob Agents Chemother. 2012 Nov;56(11):5858-64. doi: 10.1128/AAC.01406-12. Epub 2012 Sep 4.

PMID:
22948867
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.

Baatz F, Struck D, Lemaire M, De Landtsheer S, Servais JY, Arendt V, Schmit JC, Perez Bercoff D.

Antiviral Res. 2011 Dec;92(3):488-92. doi: 10.1016/j.antiviral.2011.10.003. Epub 2011 Oct 13.

PMID:
22020304
[PubMed - indexed for MEDLINE]
9.

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.

Bon I, Clò A, Borderi M, Colangeli V, Calza L, Morini S, Miserocchi A, Cricca M, Gibellini D, Re MC.

Int J Infect Dis. 2013 Oct;17(10):e875-82. doi: 10.1016/j.ijid.2013.02.020. Epub 2013 Apr 15.

PMID:
23597487
[PubMed - indexed for MEDLINE]
Free Article
10.

Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.

Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, Goodrich J.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):558-64. doi: 10.1097/QAI.0b013e3181ee3d82.

PMID:
20703158
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.

Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, McLaughlin B, Landay AL, Adeyemi O, Gilman LE, Clagett B, Rodriguez B, Martin JN, Schacker TW, Shacklett BL, Palmer S, Lederman MM, Deeks SG.

Blood. 2013 Jun 6;121(23):4635-46. doi: 10.1182/blood-2012-06-436345. Epub 2013 Apr 15.

PMID:
23589670
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.

Ruiz-Mateos E, González-Serna A, Genebat M, Machmach K, Vidal F, Muñoz-Fernández A, Ferrando-Martinez S, Leal M.

Antimicrob Agents Chemother. 2011 Oct;55(10):4664-9. doi: 10.1128/AAC.00753-11. Epub 2011 Aug 1.

PMID:
21807977
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256.

Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR.

J Infect Dis. 2012 Aug 15;206(4):534-42. doi: 10.1093/infdis/jis376. Epub 2012 Jun 27.

PMID:
22740718
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.

Arberas H, Guardo AC, Bargalló ME, Maleno MJ, Calvo M, Blanco JL, García F, Gatell JM, Plana M.

J Antimicrob Chemother. 2013 Mar;68(3):577-86. doi: 10.1093/jac/dks432. Epub 2012 Nov 14.

PMID:
23152485
[PubMed - indexed for MEDLINE]
Free Article
15.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

PMID:
18832245
[PubMed - indexed for MEDLINE]
Free Article
16.

Clinical utility of maraviroc.

Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA.

Clin Drug Investig. 2011;31(8):527-42. doi: 10.2165/11590700-000000000-00000. Review.

PMID:
21595497
[PubMed - indexed for MEDLINE]
17.

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M.

J Virol. 2007 Mar;81(5):2359-71. Epub 2006 Dec 20.

PMID:
17182681
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.

Ndegwa S.

Issues Emerg Health Technol. 2007 Dec;(110):1-8.

PMID:
18080399
[PubMed - indexed for MEDLINE]
19.

Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.

Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.

Antivir Ther. 2011;16(3):395-404. doi: 10.3851/IMP1759.

PMID:
21555822
[PubMed - indexed for MEDLINE]
20.

Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Espirito-Santo M, Santos-Costa Q, Calado M, Dorr P, Azevedo-Pereira JM.

AIDS Res Hum Retroviruses. 2012 May;28(5):478-85. doi: 10.1089/AID.2011.0124. Epub 2011 Oct 3.

PMID:
21902586
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk